Analyst Price Target is GBX 2,068.75
▲ +4.59% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Hikma Pharmaceuticals in the last 3 months. The average price target is GBX 2,068.75, with a high forecast of GBX 2,150 and a low forecast of GBX 2,000. The average price target represents a 4.59% upside from the last price of GBX 1,978.
Current Consensus is
Moderate Buy
The current consensus among 6 contributing investment analysts is to moderate buy stock in Hikma Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.
Read More
